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Abstract
Background: Irisin is a recently identified myokine that plays an important role in preventing obesity and insulin
resistance. We investigated whether the common FNDC5 (irisin precursor) gene variants influence susceptibility to
obesity and type 2 diabetes (T2D) and verified the impact of FNDC5 gene variants on serum irisin levels, glucose
and lipid metabolism in a Saudi population.
Methods: Genomic DNA from 814 (394 T2DM and 414 controls) subjects were genotyped for the five common
SNPs (rs3480A/G, rs1746661G/T, rs1298190A/G, rs726344A/G and rs1570569G/T) of the FNDC5 gene using the
TaqMan genotyping assay. Biochemical parameters and hematic concentrations of irisin and insulin as well as
anthropometric indices were collected.
Results: Serum irisin levels were higher in T2DM patients compared to controls (p < 0.0001). Analyses of FNDC5
SNPs showed that: 1) The rs3480 GG associates with decreased risk of obesity (p = 0.005; odds ratio: 0.48) and lower
body mass index (BMI) values (p = 0.03). In addition, GGAAG was identified as the protective haplotype against
risk of obesity (p = 0.001; odds ratio: 0.23). 2) The rs1746661 G allele associates with higher triglyceride (TG) levels
(p = 0.019). 3) The rs157069 TT genotype associates with higher fasting insulin (p = 0.029) and HOMA-IR (p = 0.002)
as well as with lower circulating irisin levels (p = 0.016).
Conclusions: SNPs in FNDC5 gene correlates with obesity and glucose-lipid metabolism possibly because they
modulate the serum levels of irisin.
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Background
Obesity and insulin resistance play important roles in
the pathogenesis of type 2 diabetes mellitus (T2DM) and
are associated with cardiovascular disease [1, 2]. Imbal-
ance between energy intake and energy expenditure may
cause individuals to be underweight, overweight, or
obese [3, 4]. Both skeletal muscle and adipose tissue
have been shown to function as endocrine organs by se-
creting hormones called myokines and adipokines,
respectively, and the cross-talk between them is critical
for body weight and metabolism [5]. Adipose tissue is
composed of two distinct compartments; white adipose
tissue (WAT) and brown adipose tissue (BAT). WAT is
involved in the regulation of energy homeostasis through
the storage of excess energy, whereas BAT exert a
thermogenic activity, and regulates body temperature by
dissipating energy through heat production [6, 7]. Thus,
browning of adipose tissue is hypothesized to improve
insulin sensitivity and decrease weight gain [4].
Irisin, a newly described exercise-mediated myokine
regulates energy metabolism by converting white into
brown fat, may contribute to muscle-adipose tissue
cross-talk [5, 8]. Irisin is produced upon cleavage of the
precursor plasma membrane protein fibronectin type III
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domain-containing protein 5 (FNDC5) and enters the cir-
culation [9]. In rodents, overexpression of adenoviral
FNDC5 in high-fat diet fed mice results in increased en-
ergy expenditure, improved obesity (reduced body weight)
and insulin resistance [10]. Furthermore, irisin is reported
to be involved in the pathogenesis of several complications
of obesity including dyslipidemia, T2DM, arterial hyper-
tension and metabolic Syndrome [11]. However, there are
discrepancies regarding the relation of irisin especially
with obesity and T2DM. In some studies, a positive
association was detected between irisin levels and
BMI [9, 12, 13], while others reported null [14, 15] or
a negative correlation [11, 12, 16]. From the above men-
tioned studies, it is evident that either irisin or its precur-
sor (FNDC5) has a role to play in pathogenesis of
metabolic diseases, including diabetes and obesity.
Until now, only three previous genetic studies have in-
vestigated the association of common SNPs in FNDC5
with obesity [17], insulin sensitivity [18] and glucose me-
tabolism [19]. Because of the pivotal role of irisin/
FNDC5 in obesity, insulin resistance and T2DM, we aim
to evaluate a possible role of five FNDC5 polymorphisms
(rs3480A/G, rs1746661G/T, rs1298190A/G, rs726344A/
G and rs1570569G/T) in obesity and T2DM phenotypes
from Saudi Arabia, a region with a high prevalence of
both conditions [20, 21]. In addition, we examined
whether FNDC5 gene variants has any influence on
serum irisin expression and clinical traits related to glu-
cose and lipid metabolism.
Results
The anthropometric, clinical and biochemical features of
individuals enrolled in the study are presented in Table 1.
All the analyzed SNPs (rs3480, rs1746661, rs1570569
and rs1298190) were in Hardy-Weinberg equilibrium in
our population (p > 0.05) except rs726344. The role of
these common FNDC5 gene variants in predisposition
to T2DM was analyzed next by multiple logistic regres-
sion model using age, gender, and BMI as covariates. Re-
sults indicated that none of these SNPs were associated
with T2DM (Table 2). We then analyzed the distribution
of these SNPs in two BMI-based subgroups, namely,
obese or lean. Logistic regression indicated that the
rs3480 GG genotype is protective against obesity (p =
0.005; OR, 0.48; 95 % CI, 0.28-0.79) (Table 3). This was
confirmed by a significant association of the same GG
genotype of rs3480 with lower BMI values (p = 0.03)
(Table 4). In addition, the distribution frequencies of
rs3480 _G + rs1746661_G + rs1298190 _A + rs726344
_A + rs1570569_G (i.e. GGAAG) haplotype was signifi-
cantly different in obese compared to lean individuals;
notably, this haplotype is significantly associated with
reduced obesity risk (p = 0.001; OR, 0.23; 95 % CI, 0.10–
0.53) (Table 5). However, no such differences were
observed in T2DM group for any of the examined
haplotypes (Table 5).
To determine the effect of FNDC5 SNPs on clinical
and biochemical parameters, we analyzed the distribu-
tion of these variables in relation to the various geno-
types. After controlling for age, gender, BMI and
T2DM, we observed that the rs1746661 G allele was sig-
nificantly associated with higher triglycerides (TG) levels
(p = 0.019) (Table 4). Similarly, the rs3480 AA genotype
was associated with higher HDL-Cholesterol levels.
Finally, the rs1570569 TT genotype was significantly asso-
ciated with higher fasting serum insulin (p = 0.029) and
Table 1 Anthropometric and metabolic characteristics of subjects
Group Sub-group
Variables T2DM Non-T2DM Obese Lean
(N = 394) (N = 420) (N = 293) (N = 264)
Male/Female 234/160 188/232 121/172 150/114
Age (years) 53.5 ± 11.2 44.3 ± 12.7** 47.8 ± 11.12 48.4 ± 14.9
BMI (kg/m2) 29.5 ± 6.0 27.2 ± 5.3** 34.9 ± 4.39 21.7 ± 2.8**
Systolic BP (mmHg) 128.8 ± 15.1 117 ± 14.0** 125.4 ± 14.2 119 ± 14.3**
Diastolic BP (mmHg) 80.6 ± 9.2 77.1 ± 10.1** 79.7 ± 10.2 75.4 ± 7.7**
Total Cholesterol (mmol/l) 5.3 ± 1.17 5.0 ± 1.17** 5.18 ± 1.1 5.17 ± 1.2
Triglycerides (mmol/l) 1.7 ± 0.6 1.3 ± 0.56** 1.5 ± 0.57 1.45 ± 0.61*
Glucose (mmol/l) 10.1 ± 3.59 5.1 ± 0.93** 10.1 ± 3.59 5.1 ± 0.93*
HDL-Cholesterol (mmol/) 0.85 ± 0.34 0.92 ± 0.40* 0.90 ± 0.37 0.87 ± 0.39
LDL-Cholesterol (mmol/) 3.63 ± 1.0 3.56 ± 1.0 3.60 ± 1.0 3.56 ± 1.0
Insulin (μIU/mL) 15.08 ± 9.0 15.9 ± 9.1 17.6 ± 9.4 10.6 ± 6.3**
HOMA-IR 6.88 ± 5.5 3.7 ± 2.35** 6.35 ± 4.4 3.0 ± 2.1**
Note: “**” denotes p < 0.001, “*” represents p < 0.01. Independent sample t-test was used to compute the difference between studied groups. Data were presented
as mean ± standard deviation. Insulin and HOMA-IR are log transformed prior to analysis. Insulin and HOMA-IR values were available for 392 subjects
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HOMA-IR values (p = 0.002) (Table 4). Importantly, all
the associations remained significant after Bonferroni
correction.
Serum irisin levels were analyzed in a randomly se-
lected subgroup of 88 T2DM and 119 controls sub-
jects. Significantly higher circulating irisin levels were
observed in the T2DM than in non-T2DM subjects
(p < 0.001) (Fig. 1a), whereas, no such differences were
observed in obese and lean group (Fig. 1b). Assess-
ment of possible associations between FNDC5 SNPs
and serum irisin levels after adjusting age, gender,
BMI and T2DM showed that the FNDC5 rs1570569
TT genotype was associated with lower serum irisin
levels (p = 0.016) (Table 4).
Discussion
In the attempt to shed light on the relationship between
irisin (FNDC5 gene), T2DM and obesity, we performed
genetic analysis (SNP) on a cohort of 394 T2D and 293
obese individuals, comparing the results to those ob-
tained in healthy controls. Results showed that rs3480,
an intronic variant in FNDC5 gene, is protective against
obesity. Additional data indicated that higher circulating
irisin levels were found in T2DM patients, and that vari-
ants of the FNDC5 gene modulate circulating irisin
levels and glucose-lipid profile.
Irisin, a novel myokine expressed in skeletal muscle is
stimulated by exercise. This hormone exerts beneficial
effects on metabolism by inducing the browning of sub-
cutaneous white adipocytes and contributes to the organ
crosstalk, which is essential to maintain metabolic
homeostasis [22, 23]. Both in culture and mouse models,
FNDC5 induces browning of subcutaneous adipocytes
and thermogenesis by increasing uncoupling protein 1
(UCP1) levels [10]. Serum irisin has been linked to a var-
iety of disorders, including obesity, insulin sensitivity
and T2DM [12, 18, 24]. Furthermore, it has also been re-
ported that the SNPs in FNDC5 modulates glucose me-
tabolism and insulin sensitivity [17–19]. To the best of
our knowledge, the relationship between variants of
FNDC5 (Irisin) and its association with T2DM and obes-
ity phenotypes in the Saudi Arabian population has not
been previously studied. Remarkably, results of our study
showed the presence of a strong association between the
FNDC5 rs3480 (GG) genotype and a reduced risk (pro-
tection) of obesity, independent of age, gender and
T2DM. A confirmation of this finding was obtained by
Table 2 Genotype distribution in T2DM vs Non-T2DM subjects
T2DM (%) Non-T2DM (%) Odds ratio (95 CI) P-value
rs3480 A/G
GG 78 (20.7) 88 (21.5) 1.29 (0.82–2.03) 0.26
AG 181 (48.1) 186 (45.4) 1.34 (0.93–1.94) 0.11
AA 117 (31.1) 136 (32.2) 1.0 1.0
rs1746661 G/T
TT 27 (7.2) 25 (6.8) 1.22 (0.64–2.35) 0.53
GT 125 (33.5) 113 (30.9) 1.16 (0.81–1.67) 0.40
GG 221 (59.2) 228 (62.3) 1.0 1.0
rs1298190 A/G
GG 7 (1.8) 10 (2.4) 0.54 (0.16–1.76) 0.31
AG 85 (22.4) 90 (22) 1.10 (0.75–1.63) 0.60
AA 288 (75.8) 309 (75.6) 1.0 1.0
rs7246334 A/G
GG 2 (0.5) 1 (0.3) – –
AG 280 (75.3) 290 (74.7) – –
AA 90 (24.2) 97 (25) – –
rs1570569 G/T
TT 25 (6.6) 23 (5.6) 1.45 (0.72–2.8) 0.28
GT 132 (34.7) 139 (33.9) 1.08 (0.76–1.52 0.66
GG 223 (58.7) 248 (60.5) 1.0 1.0
Note: The genotype distribution of rs3480 (A/G), rs1746661 (G/T), rs1298190
(A/G) rs7246344 (A/G) and rs1570569 (G/T) variants of FNDC5 gene. Genotype
frequency differences between T2DM and Non-T2DM were tested for each
SNP using Chi-square test. Odds ratios (ORs) and 95 % confidence intervals for
genotypes were calculated using multinomial logistic regression analyses
considering T2DM as dependent variable adjusted for age, gender and BMI.
The most common genotype was used as the reference
Bold means reference value
Table 3 Genotype distribution in obese vs Non-obese subjects
Obese (%) Non-obese (%) Odds ratio (95 CI) P-value
rs3480 A/G
GG 49 (17.2) 66 (25.8) 0.48 (0.28–0.79) 0.005
AG 136 (47.7) 117 (45.7) 0.76 (0.50–1.15) 0.20
AA 100 (35.1) 73 (28.5) 1.0 1.0
rs1746661 G/T
TT 22 (8.7) 18 (7.0) 1.30 (0.64–2.6) 0.47
GT 83 (32.7) 83 (32.4) 1.04 (0.69–1.56) 0.82
GG 149 (59.7) 155 (60.5) 1.0 1.0
rs1298190 A/G
GG 5 (1.8) 3 (1.2) 1.25 (0.26–6.0) 0.77
AG 64 (22.5) 63 (24.5) 0.88 (0.58–1.35) 0.57
AA 216 (75.8 191 (74.3) 1.0 1.0
rs1570569 G/T
TT 19 (6.6) 13 (5.1) 1.33 (0.60–2.92) 0.47
GT 100 (35) 89 (34.8) 1.06 (0.72–1.56) 0.74
GG 167 (58.4) 154 (60.2) 1.0 1.0
Note: The genotype distribution of rs3480 (A/G), rs1746661 (G/T), rs1298190
(A/G) and rs1570569 (G/T) variants of FNDC5 gene. Genotype frequency
differences between obese and non-obese were tested for each SNP using
Chi-square test. Odds ratios (ORs) and 95 % confidence intervals for genotypes
were calculated using multinomial logistic regression analyses using obesity
as dependent variable adjusted for age, gender and T2DM. Significance was
set at p < 0.05. The most common genotype was used as the reference.
The variant rs7246344 (A/G) was excluded from analysis due to low rare
genotype frequency
Bold means reference value
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analysis of BMI values, which were lower in subjects car-
rying the alternative homozygous GG genotype. How-
ever, the exact molecular mechanism and reasons
underlying these associations remain to be elucidated.
Peroxisome proliferator-activated receptor alpha
(PPAR-α), a chief transcriptional regulator of lipid me-
tabolism, is upregulated in adipose cells treated with
FNDC5 [10]. PPAR-α upregulates the gene encoding
fibroblast growth factor 21 (FGF21), expressed within
the liver, and enhances hepatic lipid oxidation and blood
TG clearance [19]. It has also been reported that circu-
lating irisin levels are associated with serum TG, LDL-C
and total cholesterol in patients with insulin-resistant
states. [25], HDL-C in patients with chronic kidney dis-
ease [26], with FBG and HOMA-IR in children [22], sug-
gesting a possible role of irisin and its precursor FNDC5
Table 4 Differences in various metabolic parameters according to FNDC5 gene SNPs
rs3480 A/G rs1746661 G/T
Variables GG AG AA P TT GT GG P
BMI (kg/m2) 27.2 ± 6.4 28.3 ± 6.3 29.6 ± 6.5 0.030* 27.9 ± 6.6 28.2 ± 6.8 28.0 ± 6.1 0.93
Insulin (μIU/mL)# 13.54 ± 7.5 16.1 ± 9.5 15.8 ± 9.2 0.24 16.0 ± 8.4 14.8 ± 8.4 15.6 ± 9.6 0.70
HOMA-IR # 4.8 ± 3.9 5.7 ± 4.6 5.2 ± 3.9 0.17 5.8 ± 4.0 5.1 ± 3.6 5.4 ± 4.6 0.64
Glucose (mmol/l) 7.5 ± 3.5 7.3 ± 3.4 7.2 ± 3.4 0.78 7.8 ± 3.5 7.4 ± 3.4 7.4 ± 3.6 0.92
Total Cholesterol (mmol/l) 5.1 ± 1.1 5.1 ± 1.1 5.3 1 ± 1.1 0.66 5.2 ± 1.1 5.2 ± 1.2 5.2 ± 1.1 0.90
HDL-Cholesterol (mmol/l) 0.87 ± 0.3 0.84 ± 0.3 0.94 ± 0.4‡ 0.015 0.89 ± 0.3 0.85 ± 0.3 0.89 ± 0.3 0.20
Triglycerides (mmol/l) 1.45 ± 0.6 1.55 ± 0.5 1.55 ± 0.58 0.13 1.31 ± 0.5 1.58 ± 0.6 1.53 ± 0.5 0.019*
LDL-Cholesterol (mmol/l) 3.60 ± 0.9 3.55 ± 1.0 3.61 ± 1.0 0.80 3.66 ± 0.8 3.60 ± 1.1 3.57 ± 0.9 0.23
Irisin (μg/ml)# 0.70 ± 0.6 0.63 ± 0.5 0.77 ± 0.7 0.62 0.50 ± 0.3 0.77 ± 0.5 0.89 ± 0.7 0.10
rs1570569 G/T rs1298190 A/G
Variables TT GT GG P GG AG AA P
BMI (kg/m2) (mmol/l) 28.4 ± 6.4 28.4 ± 6.8 28.3 ± 6.1 0.94 28.3 ± 4.7 27.9 ± 6.2 28.4 ± 6.5 0.62
Insulin (μIU/mL)# 21.1 ± 11.5‡ 14.6 ± 8.2 15.5 ± 9.3 0.029* 14.9 ± 10.1 14.6 ± 8.8 15.8 ± 9.2 0.74
HOMA-IR# 9.5 ± 7.4‡ 5.0 ± 3.6 5.2 ± 4.1 0.002* 3.7 ± 2.1 5.4 ± 4.6 5.4 ± 4.1 0.56
Glucose (mmol/l) 8.0 ± 3.9 7.3 ± 3.3 7.3 ± 3.5 0.93 6.7 ± 2.7 7.7 ± 3.8 7.2 ± 3.4 0.40
Total cholesterol (mmol/l) 5.2 ± 1.2 5.1 ± 1.2 5.2 ± 1.1 0.73 4.8 ± 0.7 5.2 ± 1.0 5.1 ± 1.2 0.54
HDL-Cholesterol (mmol/l) 0.86 ± 0.4 0.84 ± 0 .3 0.90 ± 0.35 0.08 0.85 ± 0.2 0.85 ± 0.2 0.89 ± 0.3 0.67
Triglycerides (mmol/l) 1.44 ± 0.6 1.54 ± 0.6 1.53 ± 0.57 0.54 1.52 ± 0.58 1.51 ± 0.6 1.55 ± 0.5 0.77
LDL-Cholesterol (mmol/l) (mmol/l) 3.66 ± 1.0 3.60 ± 1.1 3.5 ± 0.98 0.85 3.48 ± 0.52 3.57 ± 0.9 3.58 ± 1.0 0.93
Irisin (μg/ml) # 0.41 ± 0.3 0.71 ± 0.6 0.72 ± 0.6 0.016* 0.90 ± 0.6 0.64 ± 0.6 0.70 ± 0.6 0.54
Note: Data were presented as mean ± SD values. #log transformed prior to analysis. Univariate general linear model adjusted for appropriate covariates such as
age, gender, BMI and T2DM. “*” indicates significance after Bonferroni correction; “‡” indicates significantly different from both the genotypes. Significance was set
at p < 0.05
Bold means significant
Table 5 Haplotype frequency of FNDC5 variants in T2DM versus non-T2DM and obese versus lean subjects
Haplotype T2DM Control Odd ratio (95 % CI) P-value Obese Lean Odd ratio (95 % CI) P-value
AGAAG 119 125 1.00 (Reference) – 95 73 1.00 (Reference) –
AGAGG 87 99 0.93 (0.63–1.35) 0.681 65 61 0.82 (0.52–1.30) 0.398
GGAAG 27 28 1.01 (0.56–1.82) 0.966 8 27 0.23 (0.10–0.53) 0.001
GGAGG 9 14 0.68 (0.28–1.62) 0.379 11 6 1.41 (0.50–3.99) 0.519
GGGAG 45 50 0.95 (0.59–1.52) 0.817 32 32 0.77 (0.43–1.37) 0.371
GTAAT 39 45 0.91 (0.55–1.50) 0.711 33 27 0.94 (0.52–1.70) 0.836
GTAGT 47 39 1.27 (0.77–2.07) 0.349 29 30 0.74 (0.41–1.35) 0.327
GTGAG 3 5 0.63 (0.15–2.69) 0.533 4 3 1.02 (0.22–4.72) 0.975
Note: Order of SNPs: rs3480A/G, rs1746661G/T, rs1298190A/G, rs726344A/G and rs1570569G/T). Pearson’s p value and OR (95 % CI) were calculated by
haplotype analysis
Bold means significant
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in regulation of lipid and glucose metabolism. Thus, we
examined the association between these metabolic pa-
rameters, known to be altered in T2DM and obesity,
and FNDC5 gene variants. Results showed that the G al-
lele of rs3480 is associated with low HDL-C levels. In
contrast, Staiger et al. [18] and Tanisawa et al. [19] did
not detect any association between rs3480 and HDL-C.
However, Tang et al. [17] have reported that rs3480 has
a trend towards association with HDL-C and LDL-C
levels in overweight subjects.
In the present study, we report that the rs1570569 TT
genotype is associated with increased fasting serum insu-
lin levels and HOMA-IR values. In contrast, Tanisawa et
al. [19] demonstrated that the G allele of rs3480 corre-
lates with high HOMA-IR levels in Japanese men. A
study by Tang et al. [17] reported the effect rs16835198
on fasting insulin was significantly modified by BMI in
the Chinese Han population. Further, a study by Staiger
et al. [18] reported SNP rs16835198 and rs726344 effects
on parameters of insulin sensitivity. However, in our
study, rs726344 was excluded from statistical analyses
due to its extremely low rare genotype frequency.
Contrary to our expectation, we detected higher
serum irisin levels in T2DM patients than non-
diabetic subjects. However, most of the previous stud-
ies in humans reported lower irisin levels in T2DM
patients [12, 16, 24, 27], although these findings were
contradicted by other investigations [11, 28]. Recently,
Kurdiova et al. [28] reported that myotubes derived from
T2DM patients showed higher FNDC5 expression and
displayed higher irisin levels media compared to that of
lean donors. In addition, Park et al. [11] also concluded
that irisin is associated with increased odds of having
metabolic syndrome and insulin resistance, suggesting
physiological compensatory mechanism that would result
in increased irisin levels in metabolic diseases due to an
underlying decreased sensitivity to irisin’s effects.
Although one study previously reported that two com-
mon SNPs (rs3480 and rs16835198) in FNDC5 locus are
not associated with serum irisin levels [19]. However,
the results from our study indicate that the subjects with
the rare rs1570569 (TT) genotype had significantly lower
circulating irisin levels. The relation we detected be-
tween rs1570569 variant and serum low irisin, high insu-
lin, and HOMA-IR levels suggest that this particular
SNP in the irisin precursor gene may affect glucose
metabolism through altering circulating irisin levels.
Because this SNP is located in the intronic region of
FNDC5 gene, this allelic variant may not directly in-
fluence the amino acid sequence of the irisin prod-
uct. However, it should be noted that introns harbor
functional polymorphisms that can influence the ex-
pression of the genes that host them by altering
mRNA stability, alternative mRNA splicing, or the
binding of transcription factors [29, 30]. Moreover,
Sanchis-Gomar et al. [30] reported that the SNP
Fig. 1 a Median circulating irisin levels in T2DM vs Non-T2DM group. b Median circulating irisin levels in obese vs lean group. Results are shown
as median values for each group
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(rs726344) in FNDC5 gene had functional signifi-
cance as the variant A-allele having higher luciferase
activity compared with the G-allele.
The reason for discrepancies in association of the
above mentioned SNPs with serum lipids, insulin,
HOMA-IR and irisin can be partially explained by fact
that the effects of SNPs on health-related phenotypes
are not consistent among diverse ethnic groups due to
differences in genetic backgrounds and allelic frequen-
cies. Thus, further studies with larger sample sizes are
needed to confirm these associations.
Conclusions
In summary, our data suggest that none of the five ana-
lyzed SNPs in FNDC5 gene showed association with
T2DM in Saudi population. However, the SNP rs3480 and
GGAAG haplotype are associated with reduced risk of
obesity. In addition, rs1746661 variant is associated
with elevated triglycerides; rs157069 is associated with
increased serum insulin and HOMA-IR values as well
as decreased circulating irisin levels. Further analyses
will be required to gain insight into the underlying
mechanisms.
Methods
Patients and controls
A total of 814 unrelated adult Saudi individuals [394
confirmed T2DM (234 males and 160 females) and 420
controls (188 males and 232 females] were randomly se-
lected from the Biomarker Screening Project in Riyadh
(RIYADH COHORT), a capital-wide epidemiological
study of over 17,000 consenting Saudis coming from dif-
ferent Primary Health Care Centers (PHCCs) in King-
dom of Saudi Arabia (KSA). Diagnosis of T2DM was
based on the World Health Organization (WHO) pro-
posed cut-off (fasting serum glucose ≥7.0 mmol/l or
126 mg/dl). Subjects with comorbidities that needed
medical attention or with medical complications (coron-
ary artery disease, nephropathy, thyroid diseases and end
stage renal or liver disease) were excluded from the study.
Using the WHO criteria, BMI was used to classify the
studied individuals into two sub-groups, that is, normal
weight (BMI <25 kg/m2), and obese (BMI ≥30 kg/m2).
Both control and T2DM patients were included in these
sub-groups. The clinical characteristics of all participants
are shown in Table 1. Written informed consent was col-
lected before inclusion in the study and ethics approval
was granted by the Ethics Committee of the College of
Science, King Saud University, Riyadh, KSA. Subjects were
recruited from their homes using a random cluster
sampling strategy. Consenting participants were then re-
quested to visit the nearest participating PHCC for question-
naire administration, anthropometric measurement and
blood extraction. A questionnaire focusing on demographic
information and past and present medical history was given
to all subjects.
Anthropometry and blood collection
Subjects were requested to visit their respective PHCCs
following overnight fasting (>10 h) for anthropometry
and blood withdrawal. Anthropometry included height
(rounded off to the nearest 0.5 cm), weight (rounded off
to the nearest 0.1 kg), waist and hip circumference (cen-
timeters), and mean systolic and diastolic blood pressure
(millimeters of Hg) (average of 2 readings). Body mass
index (BMI) was calculated as weight in kilograms di-
vided by height in square meters. Fasting blood samples
were collected and transferred immediately to a non-
heparinized tube for centrifugation. Collected serum was
then transferred to pre-labeled plain tubes, stored in ice
and delivered to the Biomarkers Research Program
(BRP) in King Saud University, Riyadh, KSA, for imme-
diate storage at −20 °C.
Biochemical analyses
Fasting glucose and lipid profile were measured using a
chemical analyzer (Konelab, Espoo, Finland). Serum
irisin and insulin was assessed using an enzyme-linked
immunosorbent assay (ELISA) for with an intra-assay
variability of <10 % and inter-assay variation of <15 %.
All fasting samples fell within the detection range.
Serum irisin and insulin were measured for 25 % and
50 % of the studied samples respectively. Quality Assur-
ance (QA) standards are maintained by ISO 9000 and
17025, whereas the QA department audits the BRP la-
boratory at regular intervals. Insulin resistance index
was estimated using the homeostasis model assessment
(HOMA), which was calculated using fasting plasma
glucose and insulin levels.
Single nucleotide polymorphism (SNP) selection and
genotyping
Based on publicly available NCBI SNP variation database
[31] we selected five tagging SNPs with global minor al-
lele frequency of < 0.05 (Additional file 1: Table S1) in a
region encompassing the FNDC5 gene and its 2 kb up
and downstream sequences.
Genotyping
Genomic DNA was isolated from whole blood using the
blood genomicPrep mini spin kit (GE healthcare Life Sci-
ences, Piscataway, NJ, USA). DNA concentration and purity
(260/280) were checked using Nano-drop spectrophotom-
eter. The five tagging SNPs (rs3480A/G, rs1746661G/T,
rs1298190A/G, rs726344A/G and rs1570569G/T) were
evaluated by allelic discrimination Real-time PCR using
pre-designed TaqMan genotyping assays from Applied Bio-
systems, Foster City, CA, USA. TaqMan assay IDs with
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context sequence (primers and probes) are presented in
Additional file 1: Table S1. Amplification reactions were
performed in a volume of 10 μL containing 1X TaqMan
genotyping Master Mix (Applied Biosystems), 1X mix of
unlabeled PCR primers and TaqMan MGB probes, and
30 ng of template DNA. All amplification and detection
was conducted on genomic DNA in 96-well PCR plates
using a Bio-Rad CFX96 Real-Time PCR Detection System
(Bio-Rad, Milan, Italy). Thermal cycling was initiated with a
denaturation step of 10 min at 95 °C, followed by 45 cy-
cles of 15 s at 95 °C and 90 s at 60 °C. After PCR was
completed, allelic discrimination was analyzed using
the Bio-Rad CFX Manager Software (Version 1.6, Bio-
Rad). Genotype assignment was determined by plotting
the end point relative fluorescent units (RFU) for one
fluorophore (allele 1 on the x-axis) against the RFU for
the other fluorophore (allele 2 on the y-axis) on the al-
lelic discrimination. All PCR reactions were set up in a
dedicated PCR area with dedicated PCR pipettes and
reagents. For validation, about thirty random samples
were re-genotyped. The results were reproducible with
no discrepancies in genotyping.
Statistical analysis
Data were analyzed using SPSS version 21.0 (IBM,
Armonk, NY, USA). Significance was set at p < 0.05. Bio-
chemical parameters were expressed as mean ± standard
deviation (SD). Hardy-Weinberg equilibrium was tested
using Chi-square test. Before carrying out parametric
statistical procedures, insulin, HOMA-IR and irisin
levels were logarithmically transformed to ensure a
normal distribution. Genotype distributions between the
cases and control subjects were compared with Chi-
square test. Odds ratios (ORs) and 95 % confidence
intervals (CIs) were calculated by multinomial logistic
regression using genotypes as the factor with sex and
age as covariates. BMI was added as a covariate when
addressing the association between T2DM and FNDC5
variants; T2DM was accounted as covariate for address-
ing the effect of SNPs on obesity. Univariate general
linear model adjusted for appropriate covariates such as
age, BMI, gender and T2DM was used to compare differ-
ent genotypes in each SNP with various parameters,
followed by Bonferroni correction. Haplotype frequencies
were estimated by Expectation–Maximization algorithm
(EM algorithm) with haplostats using R statistical package
[32]. The most common haplotype was used as the refer-
ence and rare haplotypes were dropped from the analysis.
Additional file
Additional file 1: Table S1. Details of used TaqMan assays,
chromosomal location and minor allele frequencies for the studied SNPs.
(DOCX 13 kb)
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